ArticleJournal of diabetes research2026
4-Methylesculetin Ameliorates Hepatic Insulin Resistance in HepG2 Cells Through AMPK/FOXO1, PI3K/AKT/GSK3β Pathways and SIRT1/NOX4 Axis.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 4-Methylesculetin Ameliorates Hepatic Insulin Resistance in HepG2 Cells Through AMPK/FOXO1, PI3K/AKT/GSK3β Pathways and SIRT1/NOX4 Axis.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by elevated blood glucose.
objectiveThis study is aimed at evaluating the efficacy of 4-methylesculetin in mitigating insulin resistance (IR) in HepG2 cells, thereby identifying the underlying mechanisms.
methodsAn HepG2 cell insulin resistance (IR-HepG2) model was established using high glucose and high insulin. Cell viability was evaluated via the CCK-8 test to ascertain the safety dosage, whereas the impact of 4-methylesculetin on glucose metabolism was investigated by quantifying glucose uptake and glycogen levels. The impact of 4-methylesculetin on oxidative stress within the IR-HepG2 model was assessed through the analysis of reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH-PX). To investigate the underlying mechanisms, Western blot analysis was performed to determine the protein expression levels of key molecules involved in insulin signaling and oxidative stress, including p-AMPK, AMPK, SIRT1, NOX4, p-AKT, AKT, p-GSK3β, GSK3β, p-FOXO1, FOXO1, p-GYS1, GYS1, PEPCK, GLUT2, and G6Pase.
resultsIn the IR-HepG2 model, 4-methylesculetin treatment significantly enhanced glucose consumption and glycogen synthesis (p < 0.01). It also markedly alleviated oxidative stress by increasing the activities of antioxidant enzymes SOD and GSH-PX (p < 0.05 or p < 0.01), and reducing the levels of ROS and MDA (p < 0.01). Western blot analysis revealed that these beneficial effects were mediated through the activation of the AMPK/FOXO1 and PI3K/AKT/GSK3β pathways, as well as the activation of SIRT1, which led to the suppression of NOX4.
conclusions4-Methylesculetin may ameliorate IR in HepG2 cells by improving glucose metabolism via AMPK/FOXO1 and PI3K/AKT/GSK3β pathways and attenuating oxidative stress via SIRT1/NOX4 axis. In addition, 4-methylesculetin has the potential to be a therapeutic agent for T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.